论文部分内容阅读
作者报道了65例年龄在55岁以下的复发或难治性急性白血病患者用大剂量阿糖胞苷(Ara-C)与大剂量表鬼臼毒素联合化疗的结果及其毒性反应,其中38例(41次)为急性髓细胞白血病(AML),18例为急性淋巴细胞白血病(ALL),9例为骨髓移植后复发的白血病病人。进入该研究组的病人都是常规诱导疗法失败(初治失败)、或复发者,且以前都接受过包括蒽环类药物在内的联合化疗。本方案用Ara-C 2g/m~2,静滴,维持3小时以上,2次/日,连续5天;表鬼臼毒素100mg/日,静滴,维持1小时以上,1次/日或2次/日,持续5天,治疗一个疗程。从治疗的第一
The authors report the results of 65 patients with relapsed or refractory acute leukemia patients aged 55 years or younger who were treated with high-dose cytarabine (Ara-C) combined with high-dose epipodophyllotoxin, and 38 patients with toxic reactions. (41) were acute myeloid leukemia (AML), 18 were acute lymphoblastic leukemia (ALL), and 9 were leukemia patients who had relapsed after bone marrow transplantation. All patients who entered the study group had failed conventional induction therapy (primary failure) or relapsed patients and had previously received combination chemotherapy including anthracyclines. This protocol uses Ara-C 2g/m~2, intravenous infusion, and maintains for more than 3 hours, 2 times/day for 5 consecutive days; epipodophyllotoxin 100 mg/day, instills, maintains for more than 1 hour, 1 time/day or 2 times/day for 5 days for one course of treatment. From the first treatment